Veniz XR 37.5 Tablet
Venlafaxine
37.5mg
Sun Pharmaceutical Industries Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 7.36 NPR |
Available as:
Indications
Veniz XR 37.5 Tablet is used for:
Depression, Anxiety, Panic disorder, Social anxiety disorder
Adult Dose
Oral
Depression
Adult: Conventional tab: Initially, 75 mg/day in 2 or 3 divided doses, may increase in increments of up to 75 mg/day at intervals of 4 days or more. Max: 375 mg/day.
Extended-release: Initially, 37.5-75 mg once daily; in patients initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4-7 days; dose may then be increased in increments of up to 75 mg/day at intervals of 4 days or more. Max: 225 mg/day.
Panic disorder
Adult: Extended-release: Initially, 37.5 mg once daily for a wk, may increase to 75 mg once daily after 7 days; increase in increments of up to 75 mg/day at intervals of 7 days or more. Max: 225 mg/day.
Anxiety
Adult: Extended-release: Initially, 37.5-75 mg once daily; in patients initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4-7 days; dose may then be increased in increments of up to 75 mg/day at intervals of 4 days or more. Max: 225 mg/day.
Hepatic impairment: Mild to moderate: Reduce dose by 50%.
Child Dose
Attention Deficit Disorder
<40 kg: 12.5 mg/day PO initially; increase by 12.5 mg/week; not to exceed 50 mg/day divided twice daily
>40 kg: 12.5 mg/day PO initially; increase by 25 mg/week; not to exceed 75 mg/day divided three times daily
Depression
Children: 37.5 mg/day PO initially
Adolescents: 37.5-75 mg/day PO initially
Maintenance: Children, 75-150 mg/day; adolescents, 150-300 mg/day
Renal Dose
Renal impairment: GFR <30 mL/min and patient requiring haemodialysis: Reduce dose by 50%.
Administration
Take with food
Contra Indications
Uncontrolled hypertension; high risk of serious ventricular arrhythmia.
Precautions
History of MI or unstable cardiac disease, seizure; hypomania or mania, increased intraocular pressure or at risk of acute narrow-angle glaucoma, at risk of bleeding. Renal and hepatic impairment. Gradual dose reduction is recommended rather than abrupt withdrawal. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor BP and heart rate regularly, cholesterol, mental status for depression. Closely observe for clinical worsening, suicidality and unusual changes in behaviour. Monitor for emergence of serotonin syndrome. In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 years) taking antidepressants for major depressive disorders and other psychiatric illnesses
Lactation: Enters milk; not recommended
Pregnancy-Lactation
Interactions
Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium, sibutramine, tramadol. May increase serum levels w/ CYP3A4 inhibitors (e.g. ketoconazole, atazanavir, clarithromycin). May increase serum levels of haloperidol. May decrease serum levels of indinavir. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants.
Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
Adverse Effects
Side effects of Venlafaxine :
>10%
Headache (25-38%),Nausea (21-58%),Insomnia (15-24%),Asthenia (16-20%),Dizziness (11-24%),Ejaculation disorder (2-19%),Somnolence (12-26%),Dry mouth (12-22%),Diaphoresis (7-19%),Anorexia (15-17%),Nervousness (17-26%),Anorgasmia (5-13%)
1-10%
Weight loss (1-6%),Abnormal vision (4-6%),Hypertension (2-5%),Impotence (4-6%),Paresthesia (2-3%),Tremor (1-10%),Vasodilation (2-6%),Vomiting (3-8%),Weight gain (2%),Flatulence (3-4%),Pruritus (1%),Yawning (3-8%),Dyspepsia (5-7%),Twitching (1-3%),Mydriasis (2%)
<1%
Angioedema,Agranulocytosis,Anemia,Anuria,Aneurism,Bacteremia,Myasthenia,Syncope,Suicide ideation/attempt
Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, hepatitis.
Mechanism of Action
Venlafaxine and its active metabolite O-desmethylvenlafaxine selectively inhibit the neuronal reuptake of serotonin, norepinephrine and to a lesser extent dopamine. It has minimal affinity for muscarinic, histamine, or ?1-adrenergic receptors. It appears to be as effective as standard antidepressants but w/ a lower incidence of anticholinergic, sedative and CV side effects.
Note
Veniz XR 37.5 37.5mg Tablet manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Venlafaxine. Veniz XR 37.5 is availble in Nepal.
Farmaco Nepal drug index information on Veniz XR 37.5 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.